Full-Time

Applied Scientist, Oncology Foundation Model (Intern)

Updated on 5/29/2026

Pathos

Pathos

51-200 employees

AI-powered platform for oncology drug development

Compensation Overview

$60 - $80/hr

New York, NY, USA

Hybrid

Hybrid role; up to 3-4 days onsite per week at NYC Headquarters.

Category
AI & Machine Learning (1)
Required Skills
LLM
Python
Tensorflow
Neural Networks
Pytorch
Requirements
  • PhD in Computer Science, Machine Learning, Artificial Intelligence, or a related field, or an MS with equivalent experience
  • Hands-on experience with deep learning and neural network architectures
  • Proven expertise in both pretraining and post training of large language models (e.g., LLaMA, Qwen, DeepSeek, or similar)
  • Strong publication record at top tier venues: NeurIPS, ICML, ICLR, ACL, or EMNLP
  • Deep understanding of transformer architectures, attention mechanisms, and optimization
  • Proficient in Python and deep learning frameworks (PyTorch or TensorFlow/JAX)
  • Experience with distributed training and large scale model infrastructure
  • Strong communicator, able to translate technical work for clinical and non technical audiences
Responsibilities
  • Lead the design, pretraining, and post training of large language models for oncology applications
  • Develop strategies for curating, processing, and governing oncology specific datasets at scale
  • Implement alignment techniques including RLHF, supervised fine tuning, and domain adaptation
  • Design rigorous evaluation frameworks to assess model performance, safety, and clinical relevance
  • Conduct novel research in LLM architectures and training methodologies for biomedical domains
  • Publish findings at top tier conferences and journals; communicate work to internal and external stakeholders
  • Partner with oncologists, clinical researchers, and cross functional teams throughout the model lifecycle
  • Mentor junior scientists and help build a culture of scientific rigor
Desired Qualifications
  • Experience applying LLMs to biomedical, healthcare, or life sciences domains
  • Background in computational biology, bioinformatics, or medical informatics
  • Knowledge of oncology terminology, clinical workflows, or cancer biology
  • Experience with retrieval augmented generation (RAG) or knowledge grounding techniques
  • Familiarity with model safety, alignment, and responsible AI practices
  • Track record of translating research into production systems
  • Experience with prompt engineering and instruction tuning
  • Contributions to open source ML projects
  • First author publications demonstrating research leadership

Pathos combines artificial intelligence with oncology to speed up cancer drug development. It analyzes large oncology datasets, including genomics, using advanced AI and machine learning to identify novel therapeutic targets and biomarkers, guiding the creation of more effective, personalized cancer treatments. The company collaborates with pharmaceutical and biotechnology partners to de-risk pipelines, shorten development timelines, and increase the odds of success for new cancer therapies. Pathos differentiates itself by offering an integrated data-driven platform that leverages diverse genomic and clinical data to drive target validation and biomarker discovery for partner programs. Its goal is to accelerate the delivery of better cancer treatments by turning complex data into actionable insights.

Company Size

51-200

Company Stage

Series D

Total Funding

$365M

Headquarters

Chicago, Illinois

Founded

2022

Simplify Jobs

Simplify's Take

What believers are saying

  • The $365 million Series D funds pipeline expansion and platform investment.
  • The Tempus-AstraZeneca partnership validates Pathos's multimodal oncology model commercially.
  • Foundry could accelerate asset sourcing, trial design, and biomarker selection across oncology.

What critics are saying

  • Clinical-stage oncology programs face high failure rates and long development timelines.
  • Pathos depends on external partners for data access, validation, and revenue.
  • AI-driven asset selection can fail, undermining partner trust and future deal flow.

What makes Pathos unique

  • Pathos combines oncology-specific AI with multimodal patient data and biological modeling.
  • Its Foundry platform identifies undervalued oncology assets, not just internal drug candidates.
  • Pathos builds through biopharma partnerships, including AstraZeneca, Tempus, and Novo Nordisk.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Pathos who can refer or advise you

Benefits

Hybrid Work Options

Remote Work Options

401(k) Retirement Plan

401(k) Company Match

Health Insurance

Dental Insurance

Vision Insurance

Paid Vacation

Paid Holidays

Wellness Program

Mental Health Support

Conference Attendance Budget

Professional Development Budget

Stock Options

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

3%

2 year growth

3%
GlobalData
May 16th, 2025
Pathos AI raises $365m for oncology drug development

Pathos AI has raised $365m in a Series D funding round as it prepares to widen its AI-enabled platform to advance the development of oncology drugs.

The Pharma Letter
May 16th, 2025
Pathos AI lands $365 million for AI-driven cancer drugs

Pathos AI, a US biotech specializing in artificial intelligence for cancer drug development, has raised $365 million in a series D financing round, lifting its valuation to about $1.6 billion.

The Manila Times
May 8th, 2025
Pathos AI Appoints Iker Huerga as Chief Executive Officer to Lead the Next Era of AI-Enabled Drug Development

NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) - Pathos AI, a leading AI-enabled biotech company focused on transforming drug development in oncology, today announced the appointment of Iker Huerga as Chief Executive Officer and Board Member.

Pharmaceutical Business Review
Apr 25th, 2025
Tempus AI, AstraZeneca, and Pathos AI join forces on cancer care

Tempus AI has entered into strategic partnerships with AstraZeneca and Pathos AI to develop a multimodal foundation model in oncology.

GlobalData
Apr 24th, 2025
AstraZeneca enters $200m AI cancer pact with Tempus and Pathos

AstraZeneca, Tempus and Pathos AI have signed a multi-year agreement to develop a large-scale multimodal deep learning model designed to accelerate cancer drug discovery.